注射剤市場：分子タイプ、薬剤クラス別、注射ルート、用途別 - 2025年～2030年の世界予測

注射剤市場は、2023年に5,633億米ドルと評価され、2024年には6,170億4,000万米ドルに達すると予測され、CAGR 9.86％で成長し、2030年には1兆885億5,000万米ドルに達すると予測されています。

市場セグメンテーションは医薬品業界のダイナミックなセグメントであり、ワクチン、生物製剤、インスリン、モノクローナル抗体など、針を使った方法で投与されるさまざまな製品を包含しています。注射剤の必要性は、血液中に薬剤を迅速に送達し、糖尿病、がん、自己免疫疾患などの急性疾患や正確な投与が必要な長期疾患にとって重要な、迅速な作用発現を保証することによって強調されています。用途は腫瘍学、内分泌学、神経学などの治療分野に及び、最終用途は病院、診療所、在宅医療環境、時にはペン型注射器や自動注射器による自己投与など多岐にわたる。

同市場は主に、慢性疾患の有病率の上昇、生物製剤の進歩、ワクチン需要の増加によって牽引されています。人口の高齢化とヘルスケアインフラの拡大が成長をさらに後押しします。新たなビジネスチャンスは、患者のコンプライアンスと安全性を向上させるバイオシミラー、無針送達システム、プレフィルドシリンジにあります。さらに、個別化医療が進み、デジタルヘルスソリューションを統合したスマート注射器の採用も進んでいます。しかし、市場は高コスト、厳しい規制要件、コンプライアンスや受容性に影響を及ぼす可能性のある注射剤の潜在的副作用といった課題に直面しています。また、代替ドラッグデリバリーとの競合や、注射針を用いた治療に対するためらいもハードルとなっています。

事業成長のためには、費用対効果の高い生産技術の開発、薬剤製剤の安定性の向上、注射に伴う痛みや不安を最小限に抑えるデリバリーシステムの進歩にイノベーションを集中させることができます。IoTとAIを機器に組み込むことで、リアルタイムのモニタリングとアドヒアランスの追跡が可能になり、患者の転帰が向上します。市場は依然として競合が激しく、これらの課題に対処し成長機会を活かすためには継続的な研究開発投資が必要です。企業は戦略的パートナーシップや提携を結び、ポートフォリオや市場でのプレゼンスを拡大することが推奨されます。この複雑な市場を乗り切るには、最先端のドラッグデリバリー技術や全人的な患者ケアソリューションを掘り下げ、機敏で先見性のあるアプローチが求められます。

市場力学：急速に進化する注射剤市場の主要市場インサイトを公開

注射剤市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の負担増
  • プレフィルド医薬品とセルフメディケーション医薬品の利用拡大
  • がん治療におけるドラッグデリバリーの継続的普及
• 市場抑制要因
  • 製品回収の増加
• 市場機会
  • 注射剤における急速な開発と承認
  • 注射剤に関するメーカー間の戦略的提携
• 市場の課題
  • 複雑な製造工程と注射剤の供給不足

ポーターのファイブフォース：注射剤市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、注射剤市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：注射剤市場における外部からの影響の把握

外部マクロ環境要因は、注射剤市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：注射剤市場における競合情勢の把握

注射剤市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：注射剤市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、注射剤市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の負担増大
    • プレフィルド薬剤と自己注射薬剤の使用増加
    • がん治療における制御ドラッグデリバリー媒体の継続的な実践
  • 抑制要因
    • 製品リコールの発生件数の増加
  • 機会
    • 注射剤の急速な開発と承認
    • 注射剤のメーカー間の戦略的提携
  • 課題
    • 複雑な製造工程と注射剤の不足
• 市場セグメンテーション分析
  • 薬物クラス：細胞シグナル伝達のためのサイトカイン注射用タンパク質の好感度が増加
  • 用途：自己免疫疾患の治療における注射剤の応用が拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境
• 顧客のカスタマイズ

第6章 注射剤市場：分子タイプ別

• 巨大分子
• 小分子

第7章 注射剤市場：薬剤クラス別

• 血液因子
• サイトカイン
• 免疫グロブリン
• インスリン
• モノクローナル抗体
• ペプチドホルモン

第8章 注射剤市場：注射経路別

• 筋肉内
• 眼内
• 脊髄内
• 静脈内
• 皮下

第9章 注射剤市場：用途別

• 自己免疫疾患
• 心血管疾患
• 感染症
• 神経学
• 腫瘍学
• 痛み

第10章 南北アメリカの注射剤市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の注射剤市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの注射剤市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Sun PharmaとTaroが合併契約を発表
  • Glenmarkは、人気の抗糖尿病薬リラグルチドのバイオシミラーをインドで発売しました。
  • Bristol Myerのオプジーボ注射剤が腎臓がんの臨床試験で主要目標を達成

企業一覧

• Fresenius Kabi AG
• SCHOTT PHARMA AG & CO. KGAA
• F. Hoffmann-La Roche Ltd.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Sanofi S.A.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Viatris Inc.
• AstraZeneca PLC
• Gilead Sciences, Inc.
• Daiichi Sankyo Co., Ltd.
• Ferring B.V.
• Cipla Limited
• Merck & Co., Inc.
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Novartis AG
• AbbVie Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Eli Lilly and Company
• Pfizer Inc.
• EVER Neuro Pharma GmbH
• Chiesi Farmaceutici S.p.A.
• Eagle Pharmaceuticals, Inc.
• Novo Nordisk A/S

LIST OF FIGURES

• FIGURE 1. INJECTABLE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INJECTABLE DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL INJECTABLE DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 46. CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 68. CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 72. INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 76. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 80. JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 84. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 88. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 92. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 100. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 104. THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 108. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 117. DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 121. EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 125. FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 129. FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 133. GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 137. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 140. ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 141. ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 145. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 149. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 153. NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 155. POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 156. POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 157. POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 160. QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 161. QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 165. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 169. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 177. SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 181. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 185. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 189. TURKEY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 193. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
• TABLE 197. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 199. INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Injectable Drugs Market was valued at USD 563.30 billion in 2023, expected to reach USD 617.04 billion in 2024, and is projected to grow at a CAGR of 9.86%, to USD 1,088.55 billion by 2030.

The injectable drugs market is a dynamic segment of the pharmaceuticals industry, encompassing a range of products administered by needle-based methods, including vaccines, biologics, insulin, and monoclonal antibodies, among others. The necessity of injectable drugs is underscored by their rapid delivery of medication into the bloodstream, ensuring quick onset of action, which is critical for acute conditions and long-term conditions requiring precise dosing such as diabetes, cancer, and autoimmune disorders. Applications extend to therapeutic areas like oncology, endocrinology, and neurology, with end-use spanning hospitals, clinics, home healthcare settings, and sometimes self-administration facilitated by pen injectors and auto-injectors.

The market is primarily driven by the rising prevalence of chronic diseases, advancements in biologics, and increased demand for vaccines. Aging populations and expanding healthcare infrastructure further bolster growth. Emerging opportunities lie in biosimilars, needle-free delivery systems, and prefilled syringes that improve patient compliance and safety. Furthermore, personalized medicine is advancing, as is adoption of smart injectables with integrated digital health solutions. However, the market faces challenges such as high costs, stringent regulatory requirements, and potential side effects of injectable drugs that may affect compliance and acceptance. Competition from alternative drug delivery methods and hesitation over needle-based therapy also present hurdles.

For business growth, innovation could focus on developing cost-effective production technologies, improving drug formulation stability, and advancing delivery systems that minimize pain and anxiety associated with injections. Incorporating IoT and AI into devices can offer real-time monitoring and adherence tracking, thus enhancing patient outcomes. The market remains competitive and requires ongoing R&D investment to address these challenges and capitalize on growth opportunities. Companies are encouraged to form strategic partnerships and collaborations to expand their portfolios and market presence. Navigating this complex market will demand agility and a forward-thinking approach, delving into cutting-edge drug delivery technologies and holistic patient care solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Injectable Drugs Market

The Injectable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising Burden of Chronic Diseases
  • Growing Use of Prefilled and Self-Injectable Drugs
  • Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
• Market Restraints
  • Rise in Incidences of Product Recall
• Market Opportunities
  • Rapid Developments and Approvals in Injectable Drugs
  • Strategic Alliances Among Manufacturers for Injectable Drugs
• Market Challenges
  • Complex Manufacturing Process and Shortages of Injectable Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Injectable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Injectable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Injectable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Injectable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Injectable Drugs Market

A detailed market share analysis in the Injectable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Injectable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Injectable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Fresenius Kabi AG, SCHOTT PHARMA AG & CO. KGAA, F. Hoffmann-La Roche Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Sanofi S.A., Abbott Laboratories, Bristol-Myers Squibb Company, Viatris Inc., AstraZeneca PLC, Gilead Sciences, Inc., Daiichi Sankyo Co., Ltd., Ferring B.V., Cipla Limited, Merck & Co., Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Novartis AG, AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eli Lilly and Company, Pfizer Inc., EVER Neuro Pharma GmbH, Chiesi Farmaceutici S.p.A., Eagle Pharmaceuticals, Inc., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Molecule Type, market is studied across Large Molecule and Small Molecule.
• Based on Drug Class, market is studied across Blood Factors, Cytokines, Immunoglobulin, Insulin, Monoclonal Antibodies, and Peptide Hormone.
• Based on Injection Routes, market is studied across Intramuscular, Intraocular, Intrathecal, Intravenous, and Subcutaneous.
• Based on Application, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Neurology, Oncology, and Pain.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Burden of Chronic Diseases
    • 5.1.1.2. Growing Use of Prefilled and Self-Injectable Drugs
    • 5.1.1.3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Rise in Incidences of Product Recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Rapid Developments and Approvals in Injectable Drugs
    • 5.1.3.2. Strategic Alliances Among Manufacturers for Injectable Drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Complex Manufacturing Process and Shortages of Injectable Drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
  • 5.2.2. Application: Growing application of injectable drugs for treating autoimmune diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Injectable Drugs Market, by Molecule Type

• 6.1. Introduction
• 6.2. Large Molecule
• 6.3. Small Molecule

7. Injectable Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Blood Factors
• 7.3. Cytokines
• 7.4. Immunoglobulin
• 7.5. Insulin
• 7.6. Monoclonal Antibodies
• 7.7. Peptide Hormone

8. Injectable Drugs Market, by Injection Routes

• 8.1. Introduction
• 8.2. Intramuscular
• 8.3. Intraocular
• 8.4. Intrathecal
• 8.5. Intravenous
• 8.6. Subcutaneous

9. Injectable Drugs Market, by Application

• 9.1. Introduction
• 9.2. Autoimmune Diseases
• 9.3. Cardiovascular Diseases
• 9.4. Infectious Diseases
• 9.5. Neurology
• 9.6. Oncology
• 9.7. Pain

10. Americas Injectable Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Injectable Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Injectable Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Sun Pharma and Taro announce merger agreement
  • 13.3.2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
  • 13.3.3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

Companies Mentioned

• 1. Fresenius Kabi AG
• 2. SCHOTT PHARMA AG & CO. KGAA
• 3. F. Hoffmann-La Roche Ltd.
• 4. Dr. Reddy's Laboratories Ltd.
• 5. Sun Pharmaceutical Industries Ltd.
• 6. GlaxoSmithKline PLC
• 7. Johnson & Johnson Services, Inc.
• 8. Sanofi S.A.
• 9. Abbott Laboratories
• 10. Bristol-Myers Squibb Company
• 11. Viatris Inc.
• 12. AstraZeneca PLC
• 13. Gilead Sciences, Inc.
• 14. Daiichi Sankyo Co., Ltd.
• 15. Ferring B.V.
• 16. Cipla Limited
• 17. Merck & Co., Inc.
• 18. Baxter International Inc.
• 19. Boehringer Ingelheim International GmbH
• 20. Novartis AG
• 21. AbbVie Inc.
• 22. Amgen Inc.
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Biogen Inc.
• 25. Eli Lilly and Company
• 26. Pfizer Inc.
• 27. EVER Neuro Pharma GmbH
• 28. Chiesi Farmaceutici S.p.A.
• 29. Eagle Pharmaceuticals, Inc.
• 30. Novo Nordisk A/S